Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
transforming growth factor-beta-imprinted natural killer cells
- Development stage
- Phase 2
- Lead developer
- Nationwide Children’s Hospital and Ohio State University Comprehensive Cancer Center
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Transforming growth factor-beta-imprinted natural killer cells (TGFβi NK cells) are a type of modified Natural Killer (NK) cell designed to overcome the immunosuppressive effects of Transforming Growth Factor-beta (TGF-β) within the tumor microenvironment. TGF-β is a potent immunosuppressive cytokine that typically inhibits the anti-tumor responses of NK cells. However, by activating and expanding NK cells in the presence of TGF-β, these cells undergo an "imprinting" process. This imprinting leads to a phenotype characterized by hypersecretion of pro-inflammatory cytokines, such as interferon-gamma (IFNγ) and tumor necrosis factor-alpha (TNFα), and altered cytotoxicity against tumor targets. Crucially, TGFβi NK cells exhibit decreased sensitivity to TGF-β-mediated suppression, a resistance that persists even after the removal of TGF-β. The mechanism involves a marked suppression of SMAD3 and T-bet, associated with altered chromatin accessibility, which contributes to their enhanced anti-tumor function. These modified NK cells hold potential as a cell-based immunotherapy for various cancers.
- Other names
- TGF-beta-imprinted natural killer cells
Beyond the preview
Go deeper on transforming growth factor-beta-imprinted natural killer cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on transforming growth factor-beta-imprinted natural killer cells.